Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.

Liu X, Chen W, Qi Y, Zhu Y

Open source

DOI
10.1155/2022/5702014
Published
2022
Container
Evidence-based complementary and alternative medicine : eCAM
Publisher
Not recorded
Open access
yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1155/2022/5702014,
  title = {Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.},
  author = {Liu X and Chen W and Qi Y and Zhu Y},
  year = {2022},
  journal = {Evidence-based complementary and alternative medicine : eCAM},
  doi = {10.1155/2022/5702014},
  url = {https://doi.org/10.1155/2022/5702014}
}

RIS

TY  - JOUR
TI  - Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.
AU  - Liu X
AU  - Chen W
AU  - Qi Y
AU  - Zhu Y
PY  - 2022
JO  - Evidence-based complementary and alternative medicine : eCAM
DO  - 10.1155/2022/5702014
UR  - https://doi.org/10.1155/2022/5702014
ER  - 

APA

X, L., W, C., Y, Q., & Y, Z. (2022). Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.. Evidence-based complementary and alternative medicine : eCAM. https://doi.org/10.1155/2022/5702014

Source records